Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anacor Pharmaceuticals
Data details mechanism of action for antifungal treatment
June 2nd, 2006
Anacor Pharmaceuticals, a privately held company, announced that its scientists presented AN2690's novel mechanism of action at the Society for Investigative Dermatology Annual Meeting in Philadelphia. AN2690, the first in a new class of antifungal agents, is being developed for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 7 to 10% of the U.S. population. Two additional posters detailing AN2690's discovery and preclinical development were presented. "These presentations illustrate the breadth of Anacor's boron chemistry and demonstrate that AN2690 is a potent antifungal drug, which acts directly on fungal...
Source: Medicine & Law Weekly (2006-06-02)
|
